In this context and given that a MEK inhibitor could strongly suppress TERT in RET/PTC-harboring cancer cells in the present study, it is possible that MEK inhibitors, like RET/PTC inhibitors, may also be therapeutically effective in PTC harboring the genetic duet of RET/PTC and TERT promoter mutations. The gene discussed is RET; the disease is cancer.